Shear resistant wound dressing for use in vacuum wound therapy

Information

  • Patent Grant
  • 10188555
  • Patent Number
    10,188,555
  • Date Filed
    Friday, June 24, 2016
    8 years ago
  • Date Issued
    Tuesday, January 29, 2019
    5 years ago
Abstract
A cover layer for a vacuum wound therapy dressing includes a backing layer formed from a flexible polymeric membrane and an adhesive layer for affixing the backing layer over a wound bed to provide a substantially fluid-tight seal around a perimeter of the wound bed. The cover layer is reinforced with a reinforcement layer extending to a peripheral region of the backing layer to distribute forces associated with evacuating a reservoir, as defined by or within the cover, to stimulate healing of the wound bed.
Description
BACKGROUND

1. Technical Field


The present disclosure relates generally to a wound dressing for treating an open wound with a vacuum wound therapy procedure. In particular, the disclosure relates to a wound dressing employing a reticulated or net-like reinforcement structure to protect the wound throughout the procedure.


2. Background of Related Art


The body's natural wound healing process is a complex series of events beginning at the moment of injury. Initially the body reacts by delivering proteins and other factors to the wound through the blood stream to minimize the damage. Blood clots to prevent blood loss while cells engulf bacteria and debris to carry it away from the wound site. Next, the body begins to repair itself in a stage of healing often referred to as the proliferate phase. This phase is characterized by the deposition granulation tissue in the wound bed. Granulation tissue provides a base structure over which cells may migrate inwardly from the periphery to close the wound. Finally the process ends as collagen gives strength to new tissue over time often forming a scar.


One technique for promoting the natural healing process, particularly, but not exclusively during the proliferate phase, is known as vacuum wound therapy (VWT). Application of a reduced pressure, e.g. sub-atmospheric, to a localized reservoir over a wound has been found to assist in closing the wound. The reduced pressure may be effective to promote blood flow to the area, to stimulate the formation of granulation tissue and the migration of healthy tissue over the wound by the natural process. Also a reduced pressure may assist in removing fluids exuding from the wound, which may inhibit bacterial growth. This technique has proven effective for chronic or non-healing wounds, but has also been used in for other purposes such as post-operative wound care.


The general VWT protocol provides for the introduction of a filler material into the wound to absorb exudates and promote fluid transport away from the wound bed. The wound filler may comprise such materials as non-reticulated foams, non-woven reinforcements or gauze. The wound and the absorbent wound filler material may then be covered by a flexible cover layer having an adhesive periphery that forms a substantially fluid tight seal with the healthy skin surrounding the wound. The cover layer thus defines a vacuum reservoir over the wound where a reduced pressure may be maintained over time by individual or cyclic evacuation procedures.


An aspect of concern in a VWT treatment is the management of forces generated in the dressing when a reduced pressure is applied. These forces may undesirably deform a flexible cover layer, draw the peri-wound margins into the wound and put the surrounding skin in tension. These same forces may significantly compress the absorbent filler such that it forms a rigid mass. In such a state, the filler adopts an increased tendency to adhere to the wound bed, restricts the fluid passages available for exudate transport and inhibits penetration of the reduced pressure there through. Accordingly, a need exists for a dressing suitable for use in a VWT procedure.


SUMMARY

The present disclosure describes a dressing for use in a vacuum wound therapy procedure to promote healing of a wound. The dressing includes a cover layer having an integrated support structure to manage forces associated with a VWT procedure. The cover layer includes a backing layer formed from a flexible polymeric membrane, an adhesive layer to affix the backing layer over a wound and provide to a seal around the wound bed, and a reticulated or net-like reinforcement layer affixed to the backing layer and extending to a peripheral region of the cover layer. The net-like reinforcement layer stiffens the cover layer and contributes to the ability of the cover layer to resist the deformation in the wound area commonly associated with a VWT procedure. Thus, the wound filler may be compressed to a minor degree such that it continues to provide exudate transport and vacuum penetration. The use of the net-like reinforcement layer may also lessen the degree to which the wound margin collapses, and may contribute to the manifestation of forces generated by the application of a reduced pressure as compression forces rather than shear forces. Compression forces applied to a wound is well known to be a beneficial wound treatment.


The reinforcement layer may be formed from such structures as a mesh of polyethylene terephthalatae fibers, apertured films and thermoplastic netting. The adhesive layer may be affixed to a peripheral region of the backing layer and may include an opening such that the adhesive layer does not extend to a central region of the cover layer. The adhesive layer may overlap a portion of the reinforcement layer such that the reinforcement layer is firmly affixed to the backing layer. Alternatively, the reinforcement layer may contain an appropriate adhesive coating to more firmly attach it to the backing layer. The backing layer may be formed from a polyurethane film having a thickness from about 0.8 mils to about 1.0 mils, and may include an aperture therein for facilitating connection of a vacuum port to the cover layer. The vacuum port may incorporate a filter screen defining a plurality of openings. The backing layer may be formed from a moisture vapor permeable membrane.


According to another aspect of the disclosure a wound dressing system includes a contact layer and an absorbent filler positioned in a wound bed and covered by a cover layer. A vacuum reservoir is defined between the cover layer and the wound bed. The cover layer includes a backing layer formed from a flexible polymeric membrane, an adhesive layer to affix the backing layer over a wound and provide to a seal around the wound bed, and a reinforcement layer affixed to the backing layer and extending to a peripheral region of the cover layer. A vacuum system is in fluid communication with the vacuum reservoir.


The contact layer may be formed from a conical apertured film to promote unidirectional flow of exudates from the wound. The absorbent filler material may include a single strand of a polyolefin filament. Also, the vacuum system may include a vacuum source, a collection canister and a one-way valve.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate embodiments of the present disclosure and, together with the detailed description of the embodiments given below, serve to explain the principles of the disclosure.



FIG. 1 is an exploded perspective view of a vacuum wound therapy system in accordance with the present disclosure;



FIG. 2 is an orthographic view of a wound facing side of the cover layer of FIG. 1;



FIG. 3 is an exploded cross sectional view taken along the line 3-3 of FIG. 2;



FIG. 4A is a cross sectional view of the vacuum wound therapy system of FIG. 1 installed over wound on a patient prior to application of a reduced pressure;



FIG. 4B is a cross sectional view of the vacuum wound therapy system of FIG. 1 installed over wound on a patient following an application of a reduced pressure;



FIG. 5 is a top plan view of a vacuum port of FIG. 1;



FIG. 6 is a perspective view of the vacuum port of FIG. 5;



FIG. 7 is a perspective view of an alternative embodiment of a vacuum port;



FIG. 8 is an exploded perspective view of an alternative embodiment of a vacuum port assembly including a portal member and an independent filter screen;



FIG. 8A is a perspective view of the filter screen of FIG. 8 in an alternate orientation;



FIG. 8B is a perspective view of an alternate embodiment of an independent filter screen;



FIG. 9 is a bottom plan view of the portal member of FIG. 8;



FIG. 10 is a partial cross sectional view of the vacuum port assembly assembled in a wound dressing; and



FIG. 11 is an exploded perspective view of an alternative embodiment of a vacuum port assembly including a treatment element.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

The wound dressing of the present disclosure promotes healing of a wound by providing a reservoir over the wound where a reduced pressure may be maintained. The reservoir subjects the wound to a sub-atmospheric pressure to effectively draw wound fluid, including liquid exudates, from the wound without the continuous use of a vacuum pump. Hence, vacuum pressure may be applied once, or in varying intervals depending on the nature and severity of the wound. To facilitate fluid transport from the wound, a filler material may be included within the reservoir to promote the wicking of wound fluids subject to a reduced pressure. The use of a wound dressing in this manner has been found to promote healing by reducing the probability of infection, stimulating the deposition of granulation tissue and other beneficial processes. The wound dressing of the present disclosure includes a cover layer having a reinforcement structure to enhance the effect of a vacuum wound therapy treatment.


The attached figures illustrate exemplary embodiments of the present disclosure and are referenced to describe the embodiments depicted therein. Hereinafter, the disclosure will be described in detail by explaining the figures wherein like reference numerals represent like parts throughout the several views.


Referring initially to FIG. 1, a vacuum wound therapy system according to the present disclosure is depicted generally as 10 for use on a wound “w” surrounded by healthy skin “s.” The vacuum wound therapy system 10 includes a vacuum system 12 in fluid communication with a vacuum reservoir 14 (FIG. 4A) defined by or within wound dressing 16. The vacuum system 12 includes a vacuum source 18 coupled to the dressing 16 through a one-way valve 20 and a vacuum tube 24. A collection canister 28 may be provided for wound drainage and debris. The vacuum system 12 is adapted to provide a reduced pressure to the vacuum reservoir 14 appropriate to stimulate healing of the wound “w.” A more detailed description of an appropriate vacuum system 12 is found in commonly assigned U.S. Patent Application Publication 2007/0066946, the entire contents of which are incorporated herein by reference.


A vacuum port 30, depicted in greater detail in FIG. 5 and FIG. 6, may also be included to facilitate connection of the vacuum system 12 to the dressing 16. The vacuum port 30 may be configured as a rigid or semi-rigid, low-profile component adapted to receive the vacuum tube 24 in a releasable and fluid-tight manner. The vacuum port 30 may be configured to include a wide and flexible flange 32 about its perimeter. The flange 32 permits an adhesive to be attached to either an underside of flange 32 for securement to an outer surface of cover layer 44, or to a top side of flange 32 to provide for mounting to the underside of the reinforcement layer 46. Either configuration provides a mechanism for connecting to the dressing 16. A hollow interior of the vacuum port 30 provides fluid communication between the vacuum tube 24 and the reservoir 14 defined by or within dressing 16. A connector segment 33 extends above the flange 32 for facilitating connection with the vacuum tube 24. It is envisioned that because of the possible intimate proximity of the vacuum port 30 to either reservoir 14 or wound filler 38, the performance of vacuum port 30 may be enhanced by the incorporation of a filter screen 58 as depicted in FIG. 6 and FIG. 7. Filter screen 58 may inhibit the migration of large particles that may otherwise be drawn into the vacuum port 30 and consequently create a restriction or blockage of the vacuum tube 24. The filter screen 58 may be integral to the configuration of the vacuum port 30 as part of the port flange 32. The filter screen 58 may include a number of openings, each smaller than a cross-sectional area of the vacuum tube 24 or the opening in the vacuum port 30 adapted to receive the vacuum tube 24, and collectively greater than the cross-sectional area of vacuum tube 24 or the opening in the vacuum port 30 adapted to receive the vacuum tube 24. For example, the filter screen 58 of vacuum port 30 may include four relatively large openings, while the filter screen 58A of vacuum port 30A depicted in FIG. 7 may include six relatively small openings. The openings in the filter screens 58, 58A are dimensioned to minimize the passage of tissue particles of a predetermined dimension through the respective vacuum port 30, 30A.


Another alternate embodiment of a vacuum port is depicted generally as 30B in FIGS. 8, 9, 10 and 11. Vacuum port 30B may be configured to accept a filter screen 59 or 60 as a distinct or independently manufactured component as depicted in FIGS. 8, 10 and 11. An opening or cavity 31 depicted in the plan view of FIG. 9 and shown in phantom in FIG. 8 on an underside of vacuum port 30B may be adapted to permit filter screen 59 to be permanently bonded therein such that filter screen 59 is substantially flush with the underside of vacuum port 30B. Alternatively, filter screen 60 may be bonded to the opening on the underside of vacuum port 30B. Filter screen may 60 includes a generally flat base 62 through which the openings 65 extend, and a pair lips 64 projecting from the base 62 along opposite edges of the filter screen 60. The lips 64 may be dimensioned to be flush with a patient facing under surface of the flange when received within the cavity 31. Alternatively the lips 64 may extend beyond the under surface of the flange to extend beyond the cavity 31 in the portal member 30B as depicted in FIG. 10. Filter screen 60 may exhibit an increased surface area available for bonding within cavity 31 of vacuum port 30B. Filter screen 60 may be secured within cavity 31 by bonding, cements, adhesives or the like. In one embodiment, filter screen 62 is positioned within cavity 31 with lips 64 facing toward the wound (FIGS. 8 and 10). In another embodiment, filter screen 62 is positioned within lips 64 facing toward vacuum port 30B and away from the wound (FIG. 8A). In another embodiment, base 62 is devoid of lips 64 as shown in FIG. 8B, and is substantially planar.


It is also envisioned that filter screens 59 and 60 may be provided in combination with a treatment element 61 comprising a therapeutic material as depicted in FIG. 11. Treatment element 61 may be inserted between filter screens 59, 60 and may secured to vacuum port 30B by an appropriate adhesive bond. The treatment element 61 and filter screens 59, 60 may define an insert for reception into cavity or opening 31 on the underside of portal member 30B. This arrangement may provide a convenient method of treating the wound exudate as it is drawn from the wound “w.” Treatment element 61 may comprise fibrous or granulated materials contained in a porous container or wrap to facilitate placement between filter screens 59 and 60. Treatment element 61 may include materials such as activated charcoal or other odor control or neutralizing substances. Treatment element 61 may include anti-bacterials such as polyhexamethylene biguanide (PHMB). Also, antimicrobials such as ionic metals or biguinides may be included to reduce the bio-burden of the exudate or microbials within the exudate as the exudate is drawn in to a collection canister 28. In the alternative, filter screens 59, 60 may comprise charcoal, antimicrobials, anti-odor substances.


Vacuum tube 30 may be configured to accept a variety of tubing geometries such as round, oblong or elliptical. Vacuum port 30 may be provided as a pre-affixed component of dressing 16, as part of vacuum system 12 or entirely independently. Also vacuum port 30 may not be necessary depending on the configuration of dressing 16.


Wound dressing 16 generally includes a contact layer 34, filler 38 and a reinforced cover layer 40. Reinforced cover layer 40 may be formed from a composite including a backing layer 44, a reinforcement layer 46 and an adhesive layer 48. Each layer of wound dressing 16 is described in greater detail below.


Contact layer 34 may be sufficiently conformable to be positioned in direct contact with an irregularly shaped surface of a wound bed “w.” A thin film of polyethylene or other suitable non-adherent material may form the contact layer 34 to limit the adherence of filler 38 and other substances to the wound “w.” Apertures or perforations in the film permit fluids to pass through the contact layer 34, allowing for the sub-atmospheric pressure to penetrate into the wound “w” and for exudates to flow freely out of the wound “w.” By selecting an appropriate film material, the passage of wound exudate through contact layer 34 may be controlled so as to be substantially unidirectional to prevent wound exudate from flowing back into the wound. To promote a unidirectional flow, a conical apertured film, such as those provided by Tredegar Film Products of Richmond, Va., may be selected for forming contact layer 34. This type of film is arranged with apertures positioned at the peaks of cone shaped formations in the film material such that exudate encounters the film as an array of micro-funnels in one direction and an array of collecting basins in the other. Though it is depicted in a square configuration, the shape of the contact layer 34 can be customized to better suit the wound geometry. Unidirectional flow of exudates may also be promoted by the selection of other materials including a lamination of layers having varying absorptive characteristics. One exemplary material, which may be used as a contact layer is sold under the trademark XEROFLO® by Kendall Corp., a division of Covidien.


Filler 38 may be arranged over contact layer 34 to fill wound “w” to the level of the surrounding healthy skin “s” or may over-fill the wound “w” as depicted in FIG. 4A. An absorbent material such as non-woven gauze or reticulated foam may be used for filler 38 to trap or transport any exudate that migrates through contact layer 34. An antimicrobial dressing sold under the trademark KERLIX® by Kendall Corp., a division of Covidien, may be suitable for use as filler 38. To prevent adhesion to the wound “w,” the filler 38 may also comprise a material configured such that any stray fibers do not tend to protrude through apertures of contact layer 34 where they may become engulfed by newly forming granulation tissue. One particular type of material exhibiting this characteristic is often referred to as “tow.” The manufacturing process for synthetic fibers often includes an extrusion of an indeterminate length of continuous filaments, which are spun together to form fibers. It is the continuous lengths of un-spun filaments which are referred to as tow. A single length of tow formed from a hydrophobic material such as polyolefin may be laid in the wound bed “w” to form filler 38. This arrangement allows for a complete removal of filler 38 when the dressing 16 is changed without re-injuring the wound “w.”


Cover layer 40 may be placed over the wound “w” enclosing the contact layer 34 and filler 38 therein. The periphery of cover layer 40 extends laterally beyond the perimeter of the wound bed “w” so as to contact the healthy skin “s” to form a seal over the wound “w.” As depicted in FIG. 2, adhesive layer 48 may extend to the periphery of cover layer 40 to provide the seal with the use of a medical-grade, pressure-sensitive adhesive. The adhesive layer 48 may be adapted to provide a fluid-tight and bacteria-tight seal around a peripheral region of dressing 16 such that exudate cannot escape through the edges of the dressing 16 and external air and contaminants may not enter the wound area. To provide such a barrier, the adhesive layer 48 may, for example, be on the order of 1.0 to 10 mils thick depending on the adhesive used. In general, a high peal-strength adhesive may be used to resist inadvertent lift-off, roll or “flagging,” i.e., a failure of the dressing to adhere to itself or the patient, at the edges of the cover layer 40. The adhesive defining the adhesive layer 48 may include, but is not limited to, medical grade acrylics, rubber base or silicone adhesives. Preferably, those adhesives included with the dressing sold under the trademark Polyskin II Transparent Dressings by Kendall Corp., a division of Covidien, may be used. Adhesive layer 48 forms a continuous band around the peripheral region of cover layer 40, but contains an opening such that the adhesive layer does not extend inwardly to the central areas of cover layer 40.


As depicted in FIG. 3, reinforcement layer 46 may overlap adhesive layer 48 at an outer edge such that an outer periphery of reinforcement layer 46 is firmly affixed to backing layer 44. Reinforcement layer 46 extends to a peripheral region of cover layer 40, but not necessarily to an outer perimeter of the cover layer 40. Reinforcement layer 46, particularly any portion not overlapping the adhesive layer 48, may be affixed to backing layer 44 with a light coat of an adhesive 57 applied to the appropriate side of the reinforcement layer 46 or the backing layer 44. A portion of a wound facing side 52 of the reinforcement layer 46 carries no adhesive to prevent adhesion of the cover layer 40 to the filler 38. An aperture 54 extends through the reinforcement layer 46 to permit fluid communication between the reservoir 14 and vacuum system 12.


The reinforcement layer 46 may comprise a mesh of polyethylene terephtalate (PET) fibers, which offer good liquid resistance making it suitable for use in a moist wound environment. PET fibers may be used to form woven or non-woven reinforcements having large pore sizes. Some PET reinforcement manufacturing methods provide for interlinking the fiber junctions to yield a mesh that is flexible in multiple directions and also does not unravel when cut. One such method is known as hydro-entanglement. PET reinforcements thus manufactured tend to have a high shear stiffness that may be useful in reinforcing cover layer 40. One exemplary material, which may be suitable for incorporation into reinforcement layer 46, is sold under the trademark Sontara® by DuPont. Alternatively, reinforcement layer 46 may be formed from another reinforcement or mesh structure having suitable shear stiffness. Examples of suitable structures include extruded netting and apertured films. Suitable materials for use in such alternate structures include PET, polyethylene, nylon and polypropylene. Additionally, woven structures may be used for reinforcement layer 46. Acceptable woven materials may include cotton gauze, woven acetate and nylon.


Extending to the periphery of the cover layer 40 is backing layer 44. Backing layer 44 provides a substrate to which reinforcement layer 46 and adhesive layer 48 may be affixed. An aperture 56 extends through the backing layer 44 to permit fluid communication between the reservoir 14 and vacuum system 12. Backing layer 44 may be formed from a flexible polymeric membrane to serve as a fluid barrier to allow for a sub-atmospheric pressure to be established in vacuum reservoir 14, and also as a microbial barrier preventing contaminants from entering the wound area. For example, backing layer 44 may comprise a polyurethane film having a thickness from about 0.8 mils to about 1.0 mil. Preferably, the backing layer 44 is formed from a moisture vapor permeable membrane to promote the exchange of oxygen and moisture vapor between the wound site and the atmosphere. One exemplary material is a transparent membrane sold under the trade name POLYSKIN® II by Kendall Corp., a division of Covidien. Other materials which may be suitable for use in a backing layer include the thin films marketed under the names TEGADERM™ by 3M of St. Paul, Minn. and OPSITE™ by Smith and Nephew PLC of London, UK. Reinforcement layer 46 may be configured so as not to impede the transmission of moisture vapor by including, for example, a large pore size.


As seen in FIG. 4A, reservoir 14 is defined by or within wound dressing 16 when applied to the skin Filler 38 may be included to fill the reservoir 14. Evacuating atmospheric gasses from the reservoir 14 may impart a tendency for cover layer 40 to flatten against the wound “w” as depicted in FIG. 4B. This tendency of cover layer 40 to deform may draw the peri-wound margins into the wound “w” and put the surrounding skin “s” in tension. This tendency may be counteracted or resisted by the shear stiffness in reinforcement layer 46 such that the cover layer 40 may better main its shape. Because reinforcement layer 46 extends to a peripheral region of cover layer 40 and backing layer 44 anchored to healthy skin “s,” the forces associated with evacuating reservoir 14 may be transferred beyond the perimeter of the wound “w,” and may be manifested as compression forces. Thus reinforcement layer 46 reinforces cover layer 40 and vacuum reservoir 14.


A central region of reinforcement layer 46 may be devoid of an adhesive coating, such that the reinforcement layer 46 may not tend to adhere to or disturb filler 38, particularly as the reduced pressure is removed from reservoir 14. Reinforcement layer 46 thus further protects wound “w” to promote healing throughout the evacuation cycles of a VWT procedure.


Although the foregoing disclosure has been described in some detail by way of illustration and example, for purposes of clarity or understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims
  • 1. A negative pressure wound therapy dressing comprising: a backing layer comprising a flexible polymeric membrane, the backing layer including a lower wound facing side, an upper side opposite the lower wound facing side, and an aperture extending through the backing layer;a porous layer disposed below the lower wound facing side of the backing layer;an absorbent filler, wherein the absorbent filler is configured to be in fluid communication with the porous layer and configured to collect exudate removed from a wound; anda vacuum port configured to be fluidically connected, via a tube, to a negative pressure source, wherein the vacuum port comprises: a flange having an underside and a top side, wherein the underside of the flange has an opening positioned over the aperture in the backing layer and the underside of the flange is positioned on the upper side of the backing layer; anda connector extending above the flange, the connector configured to be connected to the tube;a screen positioned across the opening on the underside of the flange configured to prevent migration of particles into the vacuum port, wherein the screen comprises openings having a size configured to prevent migration of particles into the vacuum port, the size of the openings being large enough for liquid wound exudate to pass through the screen.
  • 2. The dressing according to claim 1, wherein the porous layer is substantially liquid resistant.
  • 3. The dressing according to claim 1, wherein the porous layer comprises a reticulated material.
  • 4. The dressing according to claim 1, wherein the porous layer comprises a network of interlinked fibers that comprises a mesh formed from polyethylene terephthalate fibers (PET).
  • 5. The dressing according to claim 1, wherein the connector comprises a connector segment extending above the flange, wherein the connector segment extends radially outward parallel to a base of the flange and is configured to receive the tube.
  • 6. The dressing according to claim 1, further comprising an adhesive disposed on the lower wound facing side of the backing layer, wherein the adhesive is affixed to a peripheral region of the backing layer and includes an opening such that the adhesive does not extend to a central region of the dressing.
  • 7. The dressing according to claim 6, wherein the adhesive overlaps a portion of the porous layer such that the porous layer is affixed to the backing layer.
  • 8. The dressing according to claim 1, wherein the backing layer comprises a polyurethane film having a thickness from about 0.8 mils to about 1.0 mils.
  • 9. The dressing according to claim 1, wherein the backing layer comprises a moisture vapor permeable membrane.
  • 10. The dressing according to claim 1, wherein the absorbent filler comprises material configured to trap exudate.
  • 11. The dressing according to claim 1, in combination with the negative pressure source configured to provide reduced pressure to the wound.
  • 12. The dressing according to claim 1, further comprising a wound contact layer configured to be in direct contact with the wound, wherein the absorbent filler is configured to be positioned over the wound contact layer; wherein the wound contact layer is configured to promote a substantially unidirectional flow of fluid so as to prevent exudate removed from the wound from flowing back into the wound when vacuum is applied to the wound.
  • 13. The dressing according to claim 12, wherein the backing layer, the porous layer and the wound contact layer have a square shape.
  • 14. The dressing according to claim 1, wherein the aperture in the backing layer is located in a central region of the backing layer.
  • 15. The dressing according to claim 1, wherein the porous layer comprises an aperture that extends through the porous layer to permit fluid communication between the wound and the negative pressure source.
  • 16. The dressing according to claim 1, wherein the vacuum port comprises a cavity on an underside of the vacuum port, wherein the screen is positioned within the cavity.
  • 17. The dressing according to claim 16, wherein the screen is substantially flush with the underside of the flange.
  • 18. The dressing according to claim 1, further comprising a one-way valve positioned between the vacuum port and the negative pressure source.
  • 19. The dressing according to claim 18, wherein the one-way valve is positioned at an end of the tube located away from the backing layer and toward the negative pressure source.
  • 20. The dressing according to claim 1, wherein the screen comprises a filter configured to minimize particles of predetermined dimension from passing through the screen.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser. No. 14/948,024, filed on Nov. 20, 2015 and issued as U.S. Pat. No. 9,375,353 entitled “SHEAR RESISTANT WOUND DRESSING FOR USE IN VACUUM WOUND THERAPY”, which is a continuation application of U.S. application Ser. No. 12/402,840, filed on Mar. 12, 2009 and issued as U.S. Pat. No. 9,199,012, which claims priority to, and the benefit of, under 35 U.S.C § 119(e), U.S. Provisional Application No. 61/036,275, filed on Mar. 13, 2008 by Vitaris, the entire contents of which are being hereby incorporated by reference herein in their entirety and are to be considered a part of this specification.

US Referenced Citations (369)
Number Name Date Kind
3367332 Groves Feb 1968 A
3486504 Austin, Jr. Dec 1969 A
3568675 Harvey Mar 1971 A
3572340 Lloyd et al. Mar 1971 A
3712298 Snowdon et al. Jan 1973 A
3809086 Schachet et al. May 1974 A
3874387 Barbieri Apr 1975 A
3972328 Chen Aug 1976 A
4029598 Neisius et al. Jun 1977 A
4080970 Miller Mar 1978 A
4112947 Nehring Sep 1978 A
4112949 Rosenthal et al. Sep 1978 A
4136696 Nehring Jan 1979 A
4228798 Deaton Oct 1980 A
4266545 Moss May 1981 A
4382441 Svedman May 1983 A
4524064 Nambu Jun 1985 A
4605399 Weston et al. Aug 1986 A
4655754 Richmond et al. Apr 1987 A
4743232 Kruger May 1988 A
4813942 Alvarez Mar 1989 A
4826494 Richmond et al. May 1989 A
4846164 Martz Jul 1989 A
4969880 Zamierowski Nov 1990 A
4990137 Graham Feb 1991 A
4997438 Nipper Mar 1991 A
5056510 Gilman Oct 1991 A
5071409 Rosenberg Dec 1991 A
5100395 Rosenberg Mar 1992 A
5100396 Zamierowski Mar 1992 A
5106629 Cartmell et al. Apr 1992 A
5141503 Sewell, Jr. Aug 1992 A
5149331 Ferdman et al. Sep 1992 A
5152757 Eriksson Oct 1992 A
5160322 Scheremet et al. Nov 1992 A
5176663 Svedman et al. Jan 1993 A
5178157 Fanlo Jan 1993 A
5181905 Flam Jan 1993 A
5195977 Pollitt Mar 1993 A
5234419 Bryant et al. Aug 1993 A
5238732 Krishnan Aug 1993 A
5261893 Zamierowski Nov 1993 A
5263922 Sova et al. Nov 1993 A
D364679 Heaton et al. Nov 1995 S
5484427 Gibbons Jan 1996 A
5527293 Zamierowski Jun 1996 A
5536233 Khouri Jul 1996 A
5549584 Gross Aug 1996 A
5588958 Cunningham et al. Dec 1996 A
5599289 Castellana Feb 1997 A
5636643 Argenta et al. Jun 1997 A
5645081 Argenta et al. Jul 1997 A
5678564 Lawrence et al. Oct 1997 A
5701917 Khouri Dec 1997 A
5707499 Joshi et al. Jan 1998 A
5733305 Fleischmann Mar 1998 A
5759570 Arnold Jun 1998 A
5795584 Totakura et al. Aug 1998 A
5840049 Tumey et al. Nov 1998 A
5897541 Uitenbrock et al. Apr 1999 A
5911222 Lawrence et al. Jun 1999 A
5944703 Dixon et al. Aug 1999 A
6010524 Fleischmann Jan 2000 A
6071267 Zamierowski Jun 2000 A
6117111 Fleischmann Sep 2000 A
6135116 Vogel et al. Oct 2000 A
D434150 Turney et al. Nov 2000 S
6142982 Hunt Nov 2000 A
6168800 Dobos et al. Jan 2001 B1
6174306 Fleischmann Jan 2001 B1
6203563 Fernandez Mar 2001 B1
6261276 Reitsma Jul 2001 B1
6325788 McKay Dec 2001 B1
6345623 Heaton et al. Feb 2002 B1
6348423 Griffiths et al. Feb 2002 B1
6362390 Carlucci et al. Mar 2002 B1
6398767 Fleischmann Jun 2002 B1
6406447 Thrash et al. Jun 2002 B1
6420622 Johnston et al. Jul 2002 B1
6458109 Henley et al. Oct 2002 B1
6488643 Tumey et al. Dec 2002 B1
6500112 Khouri Dec 2002 B1
6520982 Boynton et al. Feb 2003 B1
6553998 Heaton et al. Apr 2003 B2
D475134 Randolph May 2003 S
6557704 Randolph May 2003 B1
6586653 Graeme, III et al. Jul 2003 B2
D469175 Hall et al. Aug 2003 S
D469176 Hall et al. Aug 2003 S
D478659 Hall et al. Aug 2003 S
6607495 Skalak Aug 2003 B1
6626891 Ohmstede Sep 2003 B2
6648862 Watson Nov 2003 B2
6685681 Lockwood et al. Feb 2004 B2
6695823 Lina et al. Feb 2004 B1
6695824 Howard et al. Feb 2004 B2
D488558 Hall Apr 2004 S
6719742 McCormack et al. Apr 2004 B1
6752794 Lockwood et al. Jun 2004 B2
6755807 Risk, Jr. et al. Jun 2004 B2
6764462 Risk, Jr. et al. Jul 2004 B2
6767334 Randolph Jul 2004 B1
6800074 Henley et al. Oct 2004 B2
6814079 Heaton et al. Nov 2004 B2
6824533 Risk, Jr. et al. Nov 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6856821 Johnson Feb 2005 B2
6887228 McKay May 2005 B2
6887263 Bleam et al. May 2005 B2
6936037 Bubb et al. Aug 2005 B2
6942633 Odland Sep 2005 B2
6942634 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6960181 Stevens Nov 2005 B2
6979324 Bybordi et al. Dec 2005 B2
6994702 Johnson Feb 2006 B1
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7037254 O'Connor et al. May 2006 B2
7052167 Vanderschuit May 2006 B2
7070584 Johnson et al. Jul 2006 B2
7077832 Fleischmann Jul 2006 B2
7108683 Zamierowski Sep 2006 B2
7117869 Heaton et al. Oct 2006 B2
7128719 Rosenberg Oct 2006 B2
7128735 Weston Oct 2006 B2
7144390 Hanningan et al. Dec 2006 B1
7169151 Lytinas Jan 2007 B1
7182758 McCraw Feb 2007 B2
7195624 Lockwood et al. Mar 2007 B2
7198046 Argenta et al. Apr 2007 B1
7214202 Vogel et al. May 2007 B1
7216651 Argenta et al. May 2007 B2
D544092 Lewis Jun 2007 S
7273054 Heaton et al. Sep 2007 B2
7276051 Henley et al. Oct 2007 B1
7279612 Heaton et al. Oct 2007 B1
7316672 Hunt et al. Jan 2008 B1
D565177 Locke et al. Mar 2008 S
7338482 Lockwood et al. Mar 2008 B2
7351250 Zamierowski Apr 2008 B2
7361184 Joshi Apr 2008 B2
7381211 Zamierowski Jun 2008 B2
7381859 Hunt et al. Jun 2008 B2
7396345 Knighton et al. Jul 2008 B2
7410495 Zamierowski Aug 2008 B2
7413570 Zamierowski Aug 2008 B2
7413571 Zamierowski Aug 2008 B2
7422576 Boynton et al. Sep 2008 B2
7429687 Kauth Sep 2008 B2
7429689 Chen et al. Sep 2008 B2
7438705 Karpowicz et al. Oct 2008 B2
7485112 Karpowicz et al. Feb 2009 B2
7511187 Kelly Mar 2009 B2
7569742 Haggstrom et al. Aug 2009 B2
7605298 Bechert et al. Oct 2009 B2
7615036 Joshi et al. Nov 2009 B2
7622629 Aail Nov 2009 B2
7625362 Boehringer et al. Dec 2009 B2
7670323 Hunt et al. Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7699830 Martin Apr 2010 B2
7700819 Ambrosio et al. Apr 2010 B2
7708724 Weston May 2010 B2
7722582 Lina et al. May 2010 B2
7749531 Booher Jul 2010 B2
7759537 Bishop et al. Jul 2010 B2
7759539 Shaw et al. Jul 2010 B2
7775998 Riesinger Aug 2010 B2
7779625 Joshi et al. Aug 2010 B2
7811269 Boynton et al. Oct 2010 B2
7838717 Haggstrom et al. Nov 2010 B2
7846141 Weston Dec 2010 B2
7896856 Petrosenko et al. Mar 2011 B2
7909805 Weston Mar 2011 B2
7910791 Coffey Mar 2011 B2
7922703 Riesinger Apr 2011 B2
7942866 Radl et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7964766 Blott et al. Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8007257 Heaton et al. Aug 2011 B2
8062272 Weston Nov 2011 B2
8062331 Zamierowski Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8083712 Biggie et al. Dec 2011 B2
8092436 Christensen Jan 2012 B2
8118794 Weston Feb 2012 B2
8152785 Vitaris Apr 2012 B2
8162907 Heagle Apr 2012 B2
8207392 Haggstrom et al. Jun 2012 B2
8235972 Adahan Aug 2012 B2
8241261 Randolph et al. Aug 2012 B2
8267908 Coulthard Sep 2012 B2
8282611 Weston Oct 2012 B2
8298200 Vess et al. Oct 2012 B2
8303552 Weston Nov 2012 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8425478 Olson Apr 2013 B2
8444612 Patel et al. May 2013 B2
8460255 Joshi et al. Jun 2013 B2
8535283 Heaton et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8556871 Mormino et al. Oct 2013 B2
8568386 Malhi Oct 2013 B2
8569566 Blott et al. Oct 2013 B2
8628505 Weston Jan 2014 B2
8641691 Fink et al. Feb 2014 B2
8663198 Buan et al. Mar 2014 B2
8679079 Heaton et al. Mar 2014 B2
8715256 Greener May 2014 B2
8747376 Locke et al. Jun 2014 B2
8764732 Hartwell Jul 2014 B2
8795243 Weston Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8829263 Haggstrom et al. Sep 2014 B2
8834451 Haggstrom et al. Sep 2014 B2
8834452 Hudspeth et al. Sep 2014 B2
8864748 Coulthard et al. Oct 2014 B2
8915895 Jaeb et al. Dec 2014 B2
8956336 Haggstrom et al. Feb 2015 B2
9061095 Adie et al. Jun 2015 B2
9127665 Locke et al. Sep 2015 B2
9168330 Joshi et al. Oct 2015 B2
9199012 Vitaris et al. Dec 2015 B2
9220822 Hartwell et al. Dec 2015 B2
9283118 Locke et al. Mar 2016 B2
9302033 Riesinger Apr 2016 B2
9375521 Hudspeth et al. Jun 2016 B2
9381283 Adams et al. Jul 2016 B2
9446178 Blott et al. Sep 2016 B2
9452248 Blott et al. Sep 2016 B2
9669138 Joshi et al. Jun 2017 B2
9795725 Joshi et al. Oct 2017 B2
20010031943 Urie Oct 2001 A1
20010043943 Coffey Nov 2001 A1
20020016577 Ohmstede Feb 2002 A1
20020110672 Muratore-Pallatino et al. Aug 2002 A1
20020143286 Tumey Oct 2002 A1
20020151836 Burden Oct 2002 A1
20030093041 Risk, Jr. et al. May 2003 A1
20030114818 Benecke et al. Jun 2003 A1
20030180341 Gooch et al. Sep 2003 A1
20030208149 Coffey Nov 2003 A1
20030212357 Pace Nov 2003 A1
20030212359 Butler Nov 2003 A1
20030219469 Johnson et al. Nov 2003 A1
20040006319 Lina et al. Jan 2004 A1
20040030304 Hunt et al. Feb 2004 A1
20040039415 Zamierowski Feb 2004 A1
20040057855 Gerlach et al. Mar 2004 A1
20040064132 Boehringer et al. Apr 2004 A1
20040093026 Weidenhagen et al. May 2004 A1
20040122434 Argenta et al. Jun 2004 A1
20040193218 Butler Sep 2004 A1
20040241213 Bray Dec 2004 A1
20040243042 Lipman Dec 2004 A1
20040243073 Lockwood et al. Dec 2004 A1
20050010153 Lockwood et al. Jan 2005 A1
20050020955 Sanders et al. Jan 2005 A1
20050070835 Joshi Mar 2005 A1
20050070858 Lockwood et al. Mar 2005 A1
20050085795 Lockwood et al. Apr 2005 A1
20050090787 Risk, Jr. et al. Apr 2005 A1
20050101940 Radl et al. May 2005 A1
20050177190 Zamierowski Aug 2005 A1
20050182445 Zamierowski Aug 2005 A1
20050222527 Miller et al. Oct 2005 A1
20050261643 Bybordi et al. Nov 2005 A1
20060003604 Angerpointner Jan 2006 A1
20060009744 Erdman et al. Jan 2006 A1
20060015087 Risk, Jr. et al. Jan 2006 A1
20060020234 Chou et al. Jan 2006 A1
20060039742 Cable, Jr. et al. Feb 2006 A1
20060079852 Bubb et al. Apr 2006 A1
20060100586 Karpowicz et al. May 2006 A1
20060100594 Adams et al. May 2006 A1
20060116620 Oyaski Jun 2006 A1
20060127462 Canada et al. Jun 2006 A1
20060149170 Boynton et al. Jul 2006 A1
20060155260 Blott et al. Jul 2006 A1
20070005028 Risk, Jr. et al. Jan 2007 A1
20070014837 Johnson et al. Jan 2007 A1
20070021697 Ginther et al. Jan 2007 A1
20070027414 Hoffman et al. Feb 2007 A1
20070032754 Walsh Feb 2007 A1
20070032755 Walsh Feb 2007 A1
20070032778 Heaton et al. Feb 2007 A1
20070040454 Freudenberger et al. Feb 2007 A1
20070055209 Patel et al. Mar 2007 A1
20070100308 Miyairi May 2007 A1
20070179460 Adahan Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070264520 Wood et al. Nov 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20070270737 Jennings et al. Nov 2007 A1
20070293830 Martin Dec 2007 A1
20080031748 Ihle et al. Feb 2008 A1
20080071235 Locke et al. Mar 2008 A1
20080108977 Heaton et al. May 2008 A1
20080132821 Propp et al. Jun 2008 A1
20080200857 Lawhorn Aug 2008 A1
20080200905 Heaton et al. Aug 2008 A1
20080200906 Sanders et al. Aug 2008 A1
20080208147 Argenta et al. Aug 2008 A1
20080234641 Locke et al. Sep 2008 A1
20080306456 Riesinger Dec 2008 A1
20090069759 Blott et al. Mar 2009 A1
20090125004 Shen et al. May 2009 A1
20090137973 Karpowicz et al. May 2009 A1
20090157024 Song Jun 2009 A1
20090204085 Biggie et al. Aug 2009 A1
20090227969 Jaeb et al. Sep 2009 A1
20090234306 Vitaris Sep 2009 A1
20090240185 Jaeb et al. Sep 2009 A1
20090275922 Coulthard et al. Nov 2009 A1
20090299251 Buan Dec 2009 A1
20090299306 Buan Dec 2009 A1
20100063484 Heagle Mar 2010 A1
20100125258 Coulthard et al. May 2010 A1
20100256586 Bergstrom et al. Oct 2010 A1
20100305526 Robinson et al. Dec 2010 A1
20100318052 Ha et al. Dec 2010 A1
20110004172 Eckstein et al. Jan 2011 A1
20110054421 Hartwell Mar 2011 A1
20110118683 Weston May 2011 A1
20110224631 Simmons Sep 2011 A1
20110295220 Heaton et al. Dec 2011 A1
20120041399 Blott et al. Feb 2012 A1
20120095380 Gergeley et al. Apr 2012 A1
20120095426 Visscher et al. Apr 2012 A1
20120203145 Nilsson Aug 2012 A1
20130066285 Locke et al. Mar 2013 A1
20130066289 Song et al. Mar 2013 A1
20130090615 Jaeb et al. Apr 2013 A1
20130090616 Neubauer Apr 2013 A1
20130102979 Coulthard et al. Apr 2013 A1
20130116635 Fleischmann May 2013 A1
20130138054 Fleischmann May 2013 A1
20130144230 Wu et al. Jun 2013 A1
20130150814 Buan Jun 2013 A1
20130165878 Heagle Jun 2013 A1
20130274688 Weston Oct 2013 A1
20130331822 Patel Dec 2013 A1
20130338613 Haggstrom Dec 2013 A1
20130338614 Heaton et al. Dec 2013 A1
20140100539 Coulthard et al. Apr 2014 A1
20140114268 Auguste et al. Apr 2014 A1
20140155849 Heaton et al. Jun 2014 A1
20140188061 Locke et al. Jul 2014 A1
20140200535 Locke et al. Jul 2014 A1
20140228791 Hartwell Aug 2014 A1
20140236109 Greener Aug 2014 A1
20140276490 Locke et al. Sep 2014 A1
20140276491 Luckemeyer et al. Sep 2014 A1
20140276497 Robinson Sep 2014 A1
20140309601 Hall et al. Oct 2014 A1
20140316359 Collinson et al. Oct 2014 A1
20150032035 Banwell et al. Jan 2015 A1
20150065965 Haggstrom Mar 2015 A1
20150209492 Blott et al. Jul 2015 A1
20150308994 Hammond et al. Oct 2015 A1
20160074232 Vitaris Mar 2016 A1
20160081859 Hartwell Mar 2016 A1
20160144084 Collinson et al. May 2016 A1
20170128642 Buan May 2017 A1
20170181896 Hartwell Jun 2017 A1
20170181897 Hartwell Jun 2017 A1
Foreign Referenced Citations (88)
Number Date Country
34 43 101 May 1986 DE
4 012 232 Oct 1991 DE
41 11 122 Apr 1993 DE
295 04 378 Oct 1995 DE
20 2004 017 052 Jul 2005 DE
0 020 662 Jul 1984 EP
0 257 916 Mar 1988 EP
0 340 018 Nov 1989 EP
0 358 302 Mar 1990 EP
0 853 950 Jul 1998 EP
1 452 156 Sep 2004 EP
1 476 217 Nov 2004 EP
1 955 887 Aug 2008 EP
2 079 507 Jul 2009 EP
2 252 247 Nov 2010 EP
2 021 046 Mar 2012 EP
2 462 908 Jun 2012 EP
2079507 Jan 2014 EP
2 711 034 Mar 2014 EP
2 305 325 Apr 2014 EP
2 345 437 Apr 2014 EP
2 687 245 Sep 2014 EP
2 544 642 Jan 2015 EP
2 648 668 Jan 2015 EP
2 836 711 Feb 2015 EP
1163907 Oct 1958 FR
1 255 395 Dec 1971 GB
1 549 756 Aug 1979 GB
2 195 255 Apr 1988 GB
2 235 877 Mar 1991 GB
1762940 Jan 1989 SU
WO 198001139 Jun 1980 WO
WO 198002182 Oct 1980 WO
WO 198300742 Mar 1983 WO
WO 198401904 May 1984 WO
WO 198905133 Jun 1989 WO
WO 199011795 Oct 1990 WO
WO 199219313 Nov 1992 WO
WO 199529959 Nov 1995 WO
WO 199605873 Feb 1996 WO
WO 199939671 Aug 1999 WO
WO 200185248 Nov 2001 WO
WO 2002076379 Oct 2002 WO
WO 2012143665 Oct 2002 WO
WO 2003057307 Jul 2003 WO
WO 2003101508 Dec 2003 WO
WO 2004077387 Sep 2004 WO
WO 2005009488 Feb 2005 WO
WO 2005025447 Mar 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006052338 May 2006 WO
WO 2006052839 May 2006 WO
WO 2007143060 Dec 2007 WO
WO 2008039223 Apr 2008 WO
WO 2009066105 May 2009 WO
WO 2009111657 Sep 2009 WO
WO 2009114786 Sep 2009 WO
WO 2009114790 Sep 2009 WO
WO 2009124100 Oct 2009 WO
WO 2009158128 Dec 2009 WO
WO 2009114786 Mar 2010 WO
WO 2010142959 Dec 2010 WO
WO 2010147533 Dec 2010 WO
WO 2011112724 Sep 2011 WO
WO 2011135285 Nov 2011 WO
WO 2011135286 Nov 2011 WO
WO 2011135287 Nov 2011 WO
WO 2011144888 Nov 2011 WO
WO 2012074512 Jun 2012 WO
WO 2012041296 Aug 2012 WO
WO 2012131237 Oct 2012 WO
WO 2012140378 Oct 2012 WO
WO 2013010907 Jan 2013 WO
WO 2013083800 Jun 2013 WO
WO 2013090810 Jun 2013 WO
WO 2013149078 Oct 2013 WO
WO 2013136181 Nov 2013 WO
WO 2014008348 Jan 2014 WO
WO 2014016759 Jan 2014 WO
WO 2014020440 Feb 2014 WO
WO 2014020443 Feb 2014 WO
WO 2014113504 Jun 2014 WO
WO 2014108476 Jul 2014 WO
WO 2014113253 Jul 2014 WO
WO 2014107285 Sep 2014 WO
WO 2014143488 Sep 2014 WO
WO 2015022334 Feb 2015 WO
WO 2015022340 Feb 2015 WO
Non-Patent Literature Citations (74)
Entry
US 6,216,701, 04/2001, Heaton et al. (withdrawn)
US 7,186,244, 03/2007, Hunt et al. (withdrawn)
U.S. Appl. No. 14/259,026, filed Apr. 22, 2014, Hartwell.
U.S. Appl. No. 14/276,983, filed May 13, 2014, Hartwell.
Chardack, et al., “Experimental studies on Synthetic Substitutes for Skin and Their Use in the Treatment of Burns,” vol. 155, No. 1 (128-136), 1961.
Fleischmann, “Vacuum Sealing for Treatment of Problematical Wounds”, University Surgical Clinic and Polyclinic—Accident Surgery Department, WundForum Spezial-IHW 94.
Kendall ULTEC Hydrocolloid Dressing (4″x4″), product ordering page, web page downloaded Jul. 13, 2014.
Kostiuchenok, B. M., et al., “The Vacuum Effect in the Surgical Treatment of Purulent Wounds”, The Kremlin Papers: Perspectives in Wound Care, Russian Journal: Vestnik Khirurgii, BlueSky Publishing, La Costa, California (2004), 3-4.
Membrane Filters, in 16 pages, from website: http://www.advantecmfs.com/catalog/filt/membrane.pdf#page=11 (date unknown, but believed to be copyright 2001-2011).
Protz, Kerstin: “Modern Wundauflagen unterstutzen Heilungsprozess”, Wundversorgung: Indikation and Anwendung, Geriatrie Journal 4/05, pp. 3333-3339.
Stoll, “Energetic Remedies—Cupping: Healing Within a Vacuum,” https:I/www.suite101.com/article.cfm/ energetic)remedies/74531, Apr. 13, 2005.
Svedman, “A Dressing Allowing Continuous Treatment of a Biosurface,” IRCS Medical Science: Biomedical Technology; Clinical Medicine; Surgery and Transplantation, 7, 221 (1979).
Svedman, “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation,” Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986 (125-133).
Svedman, “Irrigation Treatment of Leg Ulcers,” The Lancet, Sep. 3, 1983 (532-534).
Teder and Svedman et al., “Continuous Wound Irrigation in the Pig,” Journal of Investigative Surgery, 1990, vol. 3, pp. 399-407.
Yu A. Davydov, et al., “Bacteriological and Cy1ological Assessment of Vacuum Therapy of Purulent Wounds”, Vestnik Khirurgii, Oct. 1988, (48-52).
Yu A. Davydov, et al., “Concepts for Clinical Biological Management of the Wound Process in the Treatment of Purulent Wounds Using Vacuum Therapy,” Vestnik Khirugii, Feb. 1991, 132-135).
Yu A. Davydov, et al., “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis,” Russian Journal: Vesnik Khirurgii, Sep. 1986, (66-70).
Communication of a Notice of Opposition re EP 2 254 647 dated Apr. 26, 2016, in 1 page.
Declaration of Nadeem Bridi dated Apr. 14, 2016, in 1 page.
KCI V.A.C. ATS—An Advanced Therapy System for Wound Healing, 2007, in 8 pages.
Notice of Advice of Delivery re EP 2 254 647 dated Dec. 2, 2016, in 2 pages.
Notice of Brief Communication re EP 2 254 647 dated May 10, 2016, in 1 page.
Notice of Brief Communication re EP 2 254 647 dated May 30, 2016, in 5 pages.
Notice of Brief Communication re EP 2 254 647 dated Sep. 30, 2016, in 1 page.
Notice of Further Oppositions to Opponents re EP 2 254 647 dated Jun. 1, 2016, in 2 pages.
Notice of Opposition—Statement of Facts and Evidence re EP 2 254 647 dated Apr. 19, 2016, in 111 pages.
Reply of the Patent Proprietor to the Notice(s) of Opposition re EP 2 254 647 dated Sep. 26, 2016, in 23 pages.
Request for Change of Applicant's Representative re EP 2 254 647 dated May 4, 2016, in 4 pages.
Summons to Attend Oral Proceedings re EP 2 254 647 dated Nov. 28, 2016, in 17 pages.
U.S. Appl. No. 12/402,840, filed Mar. 12, 2009, Shear Resistant Wound Dressing for Use in Vacuum Wound Terapy, U.S. Pat. No. 9,199,012.
U.S. Appl. No. 14/948,024, filed Nov. 20, 215, Shear Resistant Wound Dressing for Use in Vacuum Wound Terapy, 9,375,353.
U.S. Appl. No. 12/402,893, filed Mar. 12, 2009, Vacuum Port for Vacuum Wound Therapy, 8,152,785.
Fleischmann, W. et al., “Vacuum Sealing: Indication, Technique and Results”, Emr J Orthop Surg Tramatol (1995) 5:37-40.
International Search Report for PCT/US09/37127 dated Dec. 23, 2009, 7 pages.
Aubrey, D.A., et al., Treatment of the Perineal Wound after Proctectomy by Intermittent Irrigation, Arch. Surg., Oct. 1984, 119, 1141-1144.
Bagautdinov, N.A., “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” in current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye. Volkov et al. (Chuvashia State University, Cheboksary, USSR 1986) pp. 94-96 (with English translation).
Bier, A., Hyperemia as a Therapeutic Agent, Ed. Dr. Gustavus M. Blech, A. Robertson & Co., Chicago 1905.
Arnljots, et al., “Irrigation Treatment in Split-thickness Skin Grafting of Intractable Leg Ulcers,” Scand J Plast Reconstr Surg 19: 211-213,1985.
Bucalo et al. “Inhibition of Cell Proliferation by Chronic Wound Fluid.” Wound Repair and Regeneration. Miami, 1993. pp. 181-186.
Chariker, M.E., et al, “Effective Management of Incisional and Cutaneous Fistulae with Closed Suction Wound Drainage,” Contemporary Surgery. Jun. 1989, pp. 59-63, vol. 34.
Edlich, R.F., et al.: “Evaluation of a New, Improved Surgical Drainage System,” The American Journal of Surgery, vol. 149, pp. 295-298, Feb. 1985.
Garcia-Rinaldi, R., et al., Improving the Efficiency of Wound Drainage Catheters, Amer. Journ. of Surg., Sep. 1975, 130, 372-373.
Gorica Zivadinovic, et al., “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Conference Papers of the 5th Timok Medical Days, Majdanpek, 1986 (161-164).
Health Technology, Literature R., “Vacuum Assisted Closure Therapy for Wound Care”, Health Technology Literature Review (Dec. 2004), 3-59.
Jeter, Katherine F., et al., “Managing Draining Wounds and Fistulae: New and Established Methods”, Chronic Wound Care, 1990, pp. 240-246.
McLaughlan, James, Sterile Microenvironment for Postoperative Wound Care, The Lancet, pp. 503-504, Sep. 2, 1978.
Meyer, MD., et al., “In Surgery, Medicine and the Specialties a Manual of its Practical Application”, Bier's Hyperemic Treatment, Second Revised Edition, W.B. Saunders Company, 1909.
Morykwas, Michael J., et al., “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation”, Ann Plast Surg 1997;38:553-562 (Dec. 10, 1996).
Mulder, GD, et al., “Clinicians' Pocket Guide to Chronic Wound Repair,” Wound Healing Publications Second Edition, 1991.
Renasys EZ System for Negative Wound Therapy, Smith & Nephew announcement, dated Feb. 24, 2009, in 3 pages.
Ryosuke Fujimoro, MD., et al., “Sponge Fixation Method for Treatment of Early Scars,” From the Department of Dermatology in the Faculty Medicine, Kyoto University, vol. 42, No. 4, Oct. 1968 (322-326).
Sames, C.P., Sealing of Wounds with Vacuum Drainage, Br. Med. Journ., Nov. 5, 1977, p. 1223, Correspondence.
Sandén, Göran MD., et al., “Staphylococcal Wound Infection in the Pig: Part II. Inoculation, Quantification of Bacteria, and Reproducibility,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989, (219-223).
Smith & Nephew, “PICO Single Use Negative Pressure Wound Therapy System”, spiral booklet, Mar. 2011, in 7 pages.
Stewart, Joanne, Ph.D., World Wide Wounds—Next generation of products for wound management—2002 (13 pages).
Svedman, et al., “Staphylococcal Wound Infection in the Pig: Part I. Course,” Annals of Plastic Surgery, vol. 23, No. 3, Sep. 1989 (212-218).
Tribble, David E. M.D., An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery New York, pp. 511-513, 1972 vol. 105.
Usupov, et al., “Active Wound Drainage,” Russian Journal: Vestnik Khirugii, Apr. 1987, (42-45).
Wu, W.S., et al. Vacuum therapy as an intermediate phase in wound closure: a clinical experience, Eur J Past Surg (2000) 23: 174-177.
Yu A. Davydov, et al., “Vacuum Therapy in treatment of Acute Purulent Diseases of Soft Tissues and Purulent Wounds,” Vestnik Khirurgii, (Surgeon's Herald), Medicine Publishers, 1986.
Nullification of the German part of European patent 2 021 046 (German file references 60 2007 021 330.4), dated Nov. 23, 2015, with translation.
Notice of Appeal and subsequently filed items re EP 2254647, dated Oct. 25-27, 2017, in 6 pages.
Summons to attend oral proceedings and annex to the communication, dated Nov. 28, 2016, in 10 pages.
Reply of the patent proprietor to the notice(s) of opposition, Auxiliary request in opposition 3-6 re EP 2254647, dated Jul. 28, 2017, in 16 pages.
Annex to an opposition letter re EP 2254647, dated Jul. 27, 2017, in 6 pages.
Written submission in preparation to oral proceedings, letter accompanying subsequently filed items re EP 2254647, dated Sep. 15, 2017, in 5 pages.
Letter accompanying subsequently filed items and oral proceedings: reply to date proposed re EP 2254647, dated Sep. 27, 2017, in 3 pages.
Information about the result or oral proceedings re EP 2254647, dated Sep. 28, 2017, in 1 page.
Minutes of the oral proceedings, Decision of the Opposition Division, Decision rejecting the opposition, and Summary of facts and submissions re EP 2254647, dated Oct. 16, 2017, in 20 pages.
International Search Report and Written Opinion, re PCT Application No. PCT/US2009/037133, dated May 18, 2009.
International Preliminary Report on Patentability, re PCT Application No. PCT/US2009/037133, dated Sep. 23, 2010.
“Technology Watch”, May 1989, in 1 page.
Hersle, K. et al., “Uses of Dextranomer Absorbent Pads After Cryosurgery of Cutaneous Malignancies”, The Journal of Dermatologic Surgery and Oncology, vol. 8, Jan. 1982, in 4 pages.
Related Publications (1)
Number Date Country
20160317357 A1 Nov 2016 US
Provisional Applications (1)
Number Date Country
61036275 Mar 2008 US
Continuations (2)
Number Date Country
Parent 14948024 Nov 2015 US
Child 15192675 US
Parent 12402840 Mar 2009 US
Child 14948024 US